Cargando…

Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase®

Detalles Bibliográficos
Autores principales:	Montastruc, Jean-Louis, Rousseau, Vanessa, Durrieu, Geneviève, Bagheri, Haleh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275655/ https://www.ncbi.nlm.nih.gov/pubmed/32506216 http://dx.doi.org/10.1007/s00228-020-02920-1

Ejemplares similares

Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study
por: Garcia, Philippe, et al.
Publicado: (2020)

Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data
por: Grandvuillemin, Aurélie, et al.
Publicado: (2020)

Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective case–noncase study
por: Chouchana, Laurent, et al.
Publicado: (2021)

Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns
por: Touafchia, Anthony, et al.
Publicado: (2021)

Adverse drug reactions reporting in Turkey and barriers: an urgent need for pharmacovigilance education
por: Khan, Zakir, et al.
Publicado: (2020)

COVID-19 vaccines: A perspective from social pharmacology
por: Montastruc, Jean-Louis, et al.
Publicado: (2021)

Adverse drug reactions associated with ivermectin use for COVID-19 reported in the World Health Organization's pharmacovigilance database
por: Campillo, Jeremy T., et al.
Publicado: (2022)

Adverse drug reactions and ivermectin in COVID-19
por: Montastruc, Jean-Louis
Publicado: (2022)

Adverse drug reaction reporting for more than a decade: The need for pharmacovigilance policy implementation in Turkey
por: Khan, Zakir, et al.
Publicado: (2022)

The completeness of adverse drug reaction reports in South Africa: An analysis in VigiBase(®)
por: Matlala, Mafora F., et al.
Publicado: (2023)

VigiAccess: Promoting public access to VigiBase
por: Shankar, Pathiyil Ravi
Publicado: (2016)

Spontaneous Reports of Serious Adverse Drug Reactions Resulting From Drug–Drug Interactions: An Analysis From the French Pharmacovigilance Database
por: Létinier, Louis, et al.
Publicado: (2021)

Infections associated with clozapine: a pharmacovigilance study using VigiBase(®)
por: Chrétien, Basile, et al.
Publicado: (2023)

Pharmacovigilance analysis of the Vigibase on antidepressants-related withdrawal syndrome in adults and adolescents
por: Gastaldon, C., et al.
Publicado: (2023)

Interactions between Medical Residents and Drug Companies: A National Survey after the Mediator® Affair
por: Montastruc, François, et al.
Publicado: (2014)

Reports of Symptoms Associated with Supraventricular Arrhythmias as a Serious Adverse Drug Reaction in the Spanish Pharmacovigilance Database
por: Pueyo-Val, Javier, et al.
Publicado: (2023)

Pharmacovigilance analysis of the Vigibase on neonatal withdrawal syndrome following in utero exposure to antidepressants
por: Gastaldon, C., et al.
Publicado: (2023)

A New Drug–Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study
por: Montastruc, Jean-Louis, et al.
Publicado: (2020)

Oxcarbazepine-induced systemic lupus erythematosus: A rare and serious adverse drug reaction to a common anticonvulsant
por: Sinha, Anwita, et al.
Publicado: (2021)

The Cost of Potentially Inappropriate Medications in Nursing Homes in West Occitanie
por: Caucat, Marie, et al.
Publicado: (2020)

Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase(®))
por: Dernoncourt, Amandine, et al.
Publicado: (2022)

Pharmacovigilance in drugs used in the treatment of drug dependence
por: Thota, Anusha, et al.
Publicado: (2017)

Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase
por: Fernandez, Silvia, et al.
Publicado: (2021)

Immune thrombocytopenia following ChAdOx1 vaccine and positive rechallenge with BNT162b2 vaccine: A case report with pharmacovigilance analysis()
por: Murarasu, Anne, et al.
Publicado: (2023)

Vaccine trials with no serious adverse reactions – estimation of upper 95% confidence intervals for likelihood of such events
por: Grech, Victor, et al.
Publicado: (2022)

COVID-19 treatments and associated adverse reactions: The need for effective strategies to strengthen pharmacovigilance system in Lower- and middle-income countries
por: Khan, Zakir, et al.
Publicado: (2022)

Pharmacovigilance and adverse drug reaction reporting perspectives among interns and postgraduates of a teaching hospital
por: Sharma, Raghava, et al.
Publicado: (2014)

Adverse cutaneous drug reactions
por: Adibi, Neda
Publicado: (2014)

Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World
por: Campillo, Jérémy T., et al.
Publicado: (2021)

Fixed Drug Eruption to Hydroxychloroquine
por: Swarnkar, Bhavya, et al.
Publicado: (2021)

Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database
por: Berthet, Stephanie, et al.
Publicado: (2011)

PDG17 Adverse Drug Reactions Associated to Hydroxychloroquine and Remdesivir in COVID-19 Patients: Analysis of Reported ADR to the Portuguese Pharmacovigilance System
por: Ivos, R., et al.
Publicado: (2021)

Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study
por: Lombardi, Niccolò, et al.
Publicado: (2018)

Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic
por: Emmanuel, Stip, et al.
Publicado: (2020)

Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)
por: Zhao, Ying, et al.
Publicado: (2022)

Pharmacovigilance in vaccines
por: Budhiraja, Salil, et al.
Publicado: (2010)

Pharmacovigilance on olanzapine
por: Lingeswaran, Anand, et al.
Publicado: (2010)

Status of adverse drug reaction monitoring and pharmacovigilance in selected countries
por: Yadav, Sachdev
Publicado: (2008)

Adverse drug reactions reporting culture in Pharmacovigilance Programme of India
por: Kalaiselvan, Vivekanandan, et al.
Publicado: (2014)

Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance
por: Sahu, Ram Kumar, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0bbqvbf9jmpclk0neqqfk8aug9